阿奇霉素对比常规治疗门诊COVID-19的多中心开放标签双臂随机优效性临床试验:ATOMIC2试验方案
ATOMIC2是一项II/III期多中心前瞻性开放标签双臂随机优效性试验,针对在英国急诊就诊但无需住院的成人COVID-19患者,比较阿奇霉素500mg口服每日一次连用14天与常规治疗。主要目标是比较随机分组后28天内死亡或需有创/无创机械通气的呼吸衰竭比例。该试验旨在确定阿奇霉素在中等严重程度临床诊断COVID-19中的临床效用。
要点
- ATOMIC2针对门诊COVID-19成人患者,比较阿奇霉素14天疗程与常规治疗。
- 主要终点为28天内死亡或需机械通气的呼吸衰竭复合比例。
- 阿奇霉素500mg口服每日一次,连用14天,随访第14天和第28天电话进行。
核心结论
- 该试验将确定阿奇霉素在中等严重程度临床诊断COVID-19患者中的临床效用。
- 结果可能在全球范围内快速适用。
研究设计与样本
- ATOMIC2为II/III期、多中心、前瞻性、开放标签、双臂随机优效性临床试验。
- 受试者为在英国急诊就诊、临床诊断COVID-19且适合门诊管理的≥18岁成人。
- 参与者按1:1随机分配至常规治疗或阿奇霉素500mg口服每日一次连用14天。
- 随访为第14天和第28天电话随访。
关键数值与推荐
- 主要目标为比较随机分组后28天内死亡或需有创/无创机械通气的呼吸衰竭比例。
- 次要目标包括PCR确诊者的死亡/呼吸衰竭、全因死亡、进展至肺炎、进展至重症肺炎、疾病峰值严重程度及血液和鼻部生物标志物机制分析。
- 阿奇霉素剂量为500mg口服每日一次,疗程14天。
临床怎么用
- 该试验针对门诊COVID-19患者,评估阿奇霉素14天疗程对比常规治疗的效果。
- 主要终点为28天内死亡或需机械通气的呼吸衰竭复合结局。
局限性
- 原文未报告样本量、效应量、P值或置信区间。
- 试验为开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19). Azithromycin was widely used to treat severe SARS-CoV and MERS-CoV, but to date, no randomised data are available in any coronavirus infections. Other ongoing trials are exploring short courses of azithromycin either in early disease, within the first 7 days of symptoms, when azithromycin's antiviral properties may be important, or late in disease when anti-bacterial properties may reduce the risk of secondary bacterial infection. However, the molecule's anti-inflammatory properties, including suppression of pulmonary macrophage-derived pro-inflammatory cytokines such as interleukins-1β, -6, -8, and -18 and cytokines G-CSF and GM-CSF may provide a distinct therapeutic benefit if given in as a prolonged course during the period of progression from moderate to severe disease. METHODS: ATOMIC2 is a phase II/III, multi-centre, prospective, open-label, two-arm randomised superiority clinical trial of azithromycin versus standard care for adults presenting to hospital with COVID-19 symptoms who are not admitted at initial presentation. We will enrol adults, ≥ 18 years of age assessed in acute hospitals in the UK with clinical diagnosis of COVID-19 infection where management on an ambulatory care pathway is deemed appropriate. Participants will be randomised in a 1:1 ratio to usual care or to azithromycin 500 mg orally daily for 14 days with telephone follow-up at days 14 and 28. The primary objective is to compare the proportion with either death or respiratory failure requiring invasive or non-invasive mechanical ventilation over 28 days from randomisation. Secondary objectives include mortality/respiratory failure in those with a PCR-confirmed diagnosis; all-cause mortality; progression to pneumonia; progression to severe pneumonia; peak severity of illness and mechanistic analysis of blood and nasal biomarkers. DISCUSSION: This trial will determine the clinical utility of azithromycin in patients with moderately severe, clinically diagnosed COVID-19 and could be rapidly applicable worldwide. TRIAL REGISTRATION: ClinicalTrials.gov NCT04381962 . Registered on 11 May 2020. EudraCT identifier 2020-001740-26 . Opened for accrual on 29 May 2020.
引用
- Hinks TSC, Barber VS, Black J, et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials. 2020. PMID: 32807209. doi:10.1186/s13063-020-04593-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。